TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Hippocampal size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: White matter structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Weight loss at 6 weeks postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Procedural Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Procedural Technical Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Placebo-corrected change-from-baseline in QTcF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Air-leak at deflation of bronchial cuff
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Air-tight seal below resting volume of bronchial cuff
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Intentions to Get Screened for Colon Cancer
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Progression-Free Survival (PFS) rate at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Thrombotic complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Complete response (CR) and minimal residual disease (MRD) negative rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nonsuicidal Self-injury Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in whole-body fatty acid oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Patient Global Impression of Improvement (PGI-1)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Bronchopulmonary dysplasia (BPD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Sensory Neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Neuropathic Pain Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Elimination of Moderate-severe Regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: hypermetabolism of the anal canal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma level of 25(OH)D3 and 1,25(OH)2D3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pharmacokinetic (PK) profile of AG-221
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression level of phosphate transporters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Modified Ashworth scale (MAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: First swing test (FST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low density lipoprotein- cholesterol (LDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall nutritional quality of purchases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in bucco-lingual dimensions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival Recession Depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall safety profile
Endpoint domain: Adverse events/effects
Primary endpoint: Degree of active knee flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in 24h average SBP and DBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduced amygdala responsiveness measured by negative face to form contrasts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduced functional connectivity density (FCD) in amygdala
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduced stress network activation during stress (MIST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Transplant related mortality
Endpoint domain: Mortality/survival
Primary endpoint: In-vivo CLE measurements of urothelium and urothelial carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proportion of patients developing radiation proctitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of subjects in each phase of chronic hepatitis B infection at enrollment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Yearly incidence of compensated and decompensated cirrhosis in the study cohort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Yearly incidence of hepatocellular carcinoma in the study cohort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of treated subjects who achieve and maintain a complete response to antiviral treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Fold Rise (GMFR) From Baseline in Antibody Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Vaccine-related Serious Adverse Experiences
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical success (<50% residual stenosis at all treatment sites)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: oral/tracheal amylase ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of transferrin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Iron overload in organs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life assessment using Kidscreen 10 Index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life assessment using The VSP-A questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Expression levels of miR-142-3p in induced sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of SL-279252
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Physical Well-being Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Social/Family Well-being Score
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in Emotional Well-being Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient-level FBR area under the ROC curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First Occurrence of Major Adverse Cardiovascular Events
Endpoint domain: Mortality/survival
Primary endpoint: Mean wake time after persistent sleep onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The change of skin moisture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: The change of skin elasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: The change of skin wrinkles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: The change of skin collagen density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: The change of skin texture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: The change of skin pores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Composite Rate of Pyrexia Related Events
Endpoint domain: Adverse events/effects
Primary endpoint: Primary Safety Events of Interest
Endpoint domain: Adverse events/effects
Primary endpoint: Manufacturing Feasibility Measures
Endpoint domain: Resource use
Primary endpoint: Adherence to WHO-advised hygiene-related protocols
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adherence to viral mitigation protocols
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pruritus severity (1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pruritus severity (2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of viral respiratory tract infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in German Cockroach-Specific Serum IgE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Who Were Alive Without Disease Progression at 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Dietary patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Somatic mutation burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum Tolerated Dose of Tandutinib Defined by Dose Limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Dose Limiting Toxicities Per Dose Level
Endpoint domain: Adverse events/effects
Primary endpoint: Tumor Response (Complete Response and Partial Response) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Gene Expression Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tissue pressure application
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tissue thickness application
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lesion transmurality application
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: degree of epithelialization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: IgG and IgM anti SARS-CoV-2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in office SBP measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants with Treatment-emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Cmax of Lu AF28996
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax of Lu AF28996
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anginal Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quality of Life Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Dyspnea Assessed by the Rose Dyspnea Questionnaire (RDQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of pure red cell aplasia (PRCA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: number of days with pain per month
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Knee Laxity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Surgical site infection 30 days postoperative
Endpoint domain: Adverse events/effects
Primary endpoint: Utilization rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Blastocyst formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in sore throat severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Count of Participants With Acute Post-operative Transfusion of Packed Red Blood Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of Participants with 2-year Local Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma Related Inpatient Hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Asthma Related Emergency Department visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Use of Oral Corticosteroids (OCS)
Endpoint domain: Adverse events/effects
Primary endpoint: Time to Pain Resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of bacterial pathogens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percent change of chest pain frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Change in Percent Predicted Forced Vital Capacity (FVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: safety pharmacokinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Plasma HIV-1 RNA Decreases From Baseline Exceeding 0.5 log10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aided Thresholds Fusion-unaided PTA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of PPD
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Residual rate of tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reaching Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Center of pressure during walking gait
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preoperative acetabular index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wiberg's mean center-edge angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DNA<20,000 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of eyes with <15 letter loss at 6-month examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of eyes with <15 letter loss at 12-month examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: significant reduction of serum methotrexate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall response rate (ORR)
Endpoint domain: Adverse events/effects
Primary endpoint: Successful Revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hernia Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Postoperative MINS incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Ratio of Serum Triglyceride to HDL-cholesterol Concentration (TG:HDLC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: SUV measurement from PET scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum circulating endothelial progenitor cells as a ratio to baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Factor VIII (FVIII) Inhibitors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximum Standardized Uptake Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target to Background Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target to Striatum Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Off-treatment durability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Microbiological Response of Eradication at Test of Cure (TOC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants Who Report 1 or More Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Discontinuing Study Drug Due to an AE
Endpoint domain: Adverse events/effects
Primary endpoint: Redo surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants Experiencing a Treatment Emergent Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Successful Vital Signs Acquisition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Events (Ocular and Systemic)
Endpoint domain: Adverse events/effects
Primary endpoint: ODS total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correction of the spinal manipulable lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum voluntary isometric contraction of the knee extensors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee extensors evoked torque during the tests at maximal current intensity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total work generated during the fatigue protocol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune host response at systemic level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immune host response at local level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean difference from baseline IPSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Utilization rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Presence of deep endometriosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Urinary biomarker (DHN-MA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CT assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of contact surface between tumor and common carotid artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of patients in whom the actual dose of sorafenib equaled the planned dose
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: MST
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants Who Experienced at Least One Adverse Event During Phase A
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Experienced at Least One Adverse Event During the Overall Study
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Discontinued From the Study Due to an Adverse Event During Phase A
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Discontinued From the Study Due to an Adverse Event During the Overall Study
Endpoint domain: Adverse events/effects
Primary endpoint: Diffusion Capacity for Carbon Monoxide (CO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Seizure-free Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Social acceptability of robot prototype
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Pain assessed with VAS scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neutralizing antibody seroconversion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Grade >= 2 radiation morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline Fibroblast growth factor 23 (pg/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) Geometric Mean Ratio of Treatment C Relative to Treatment A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) Geometric Mean Ratio of Treatment C Relative to Treatment B
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC [0-24 hours]) Geometric Mean Ratio of Treatment C Relative to Treatment A
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC [0-24 hours]) Geometric Mean Ratio of Treatment C Relative to Treatment B
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR20 Response Rate at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from baseline in working memory performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: change from baseline in selective attention performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: change from baseline in sustained attention performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: change from baseline in executive function performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: change from baseline in marksmanship performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes